samedan logo
 
 
spacer
home > pmps > winter 2021 > safe, flexible, and efficient containment
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Safe, Flexible, and Efficient Containment

The demand for, and development of, new oral solid dosage forms for oncology and hormone therapy is increasing – and so is the demand for containment solutions. When processing these highly potent substances, the protection of machine operators is paramount. At the same time, the quality of the final product is crucial since patients' health depends on it.

But how much containment is really necessary, and how can it be implemented economically and flexibly in the cost-intensive pharmaceutical industry? Ultimately, only a combination of modern and highly efficient systems with automated cleaning, proven processes, and years of expertise form the basis for successful containment.

NOEL, OEL, and OEB

The occupational exposure limit (OEL) for active substances can be determined in micrograms per cubic metre (μg/m3) by means of no observed effect level (NOEL) and the required safety factors. The OEL is the time-weighted average concentration of a substance in the air at the workplace, at which no acute or chronic damage to the health of employees is to be expected. The regulation is based on eight-hour exposure five days a week during working life.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Fritz-Martin Scholz is Product Manager for the product brand Hüttlin at Syntegon Technology. The Hüttlin portfolio includes high-shear mixer granulator systems and fluid bed systems from laboratory to production scale. Fritz-Martin holds a Master’s in Engineering and has many years of experience in R&D, product development, and product management in different industries, such as packaging technology and medical technology.
spacer
Fritz-Martin Scholz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement